Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5194370
Max Phase: Preclinical
Molecular Formula: C19H28N4O2S
Molecular Weight: 376.53
Associated Items:
ID: ALA5194370
Max Phase: Preclinical
Molecular Formula: C19H28N4O2S
Molecular Weight: 376.53
Associated Items:
Canonical SMILES: CC(=O)Nc1ncc(CN2CCC(=CC(=O)NC3CCCCC3)CC2)s1
Standard InChI: InChI=1S/C19H28N4O2S/c1-14(24)21-19-20-12-17(26-19)13-23-9-7-15(8-10-23)11-18(25)22-16-5-3-2-4-6-16/h11-12,16H,2-10,13H2,1H3,(H,22,25)(H,20,21,24)
Standard InChI Key: GHZOSIAHFXMZGX-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 376.53 | Molecular Weight (Monoisotopic): 376.1933 | AlogP: 3.07 | #Rotatable Bonds: 5 |
Polar Surface Area: 74.33 | Molecular Species: NEUTRAL | HBA: 5 | HBD: 2 |
#RO5 Violations: 0 | HBA (Lipinski): 6 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 8.01 | CX Basic pKa: 6.01 | CX LogP: 2.06 | CX LogD: 1.95 |
Aromatic Rings: 1 | Heavy Atoms: 26 | QED Weighted: 0.77 | Np Likeness Score: -1.53 |
1. Li X, Han J, Bujaranipalli S, He J, Kim EY, Kim H, Im JH, Cho WJ.. (2022) Structure-based discovery and development of novel O-GlcNAcase inhibitors for the treatment of Alzheimer's disease., 238 [PMID:35588599] [10.1016/j.ejmech.2022.114444] |
Source(1):